<p>First Turn Management LLC 在第二季度减持 Mirum Pharmaceuticals, Inc.（NASDAQ:MIRM - Free Report）股份，根据该公司最新提交给证券交易委员会的第 13F 表格，持股比例下降了 26.6%。该公司在此期间卖出了 255,256 股，持有 703,398 股公司股票。Mirum Pharmaceuticals 占 First Turn Management LLC 投资组合的 3.9%，是其第 5 大持仓。根据最新提交给证券交易委员会的文件，First Turn Management LLC 持有的 Mirum Pharmaceuticals 价值约为$24,049,000。</p>
<p>获取 <strong>Mirum Pharmaceuticals</strong> 警报：</p>
<p>一些其他对冲基金和其他机构投资者最近也增加或减少了他们对 MIRM 的持股。Quest Partners LLC 在第二季度将其对 Mirum Pharmaceuticals 的持股增加了 7,513.3%。Quest Partners LLC 现在拥有 1,142 股公司股票，价值$39,000，上季度购入了 1,127 股。StepStone Group LP 在第四季度购入了 Mirum Pharmaceuticals 的新股份，价值约为$135,000。NEOS Investment Management LLC 在第四季度购入了 Mirum Pharmaceuticals 的新股份，价值约为$220,000。中国通用资产管理有限公司在第一季度将其对 Mirum Pharmaceuticals 的持股增加了 66.0%。中国通用资产管理有限公司现在拥有 8,952 股公司股票，价值$225,000，上季度购入了 3,558 股。最后，亚利桑那州退休系统在第二季度将其对 Mirum Pharmaceuticals 的持股增加了 10.6%。亚利桑那州退休系统现在拥有 9,210 股公司股票，价值$315,000，上季度购入了 883 股。</p>
<h2>内部人士的买卖行为</h2>
<p>在其他 Mirum Pharmaceuticals 的消息中，内部人士 Pamela Vig 在 6 月 24 日星期一进行了一笔交易，卖出了 30,559 股公司股票。这些股票的平均价格为$34.00，总价值为$1,039,006.00。交易完成后，该内部人士直接持有公司股票 27,406 股，价值约为$931,804。该交易已在提交给 SEC 的文件中披露，可以通过此链接查看。公司股份的 22.87% 归公司内部人士所有。</p>
<h2>Mirum Pharmaceuticals 股票表现</h2>
<p>MIRM 股票周五开盘价为$41.13。Mirum Pharmaceuticals, Inc.的 52 周最低价为$23.14，52 周最高价为$45.23。公司的流动比率为 3.28，速动比率为 3.09，负债权益比为 1.34。公司的五十天简单移动平均为$40.46，两百天简单移动平均为$31.57。</p>
<p>Mirum Pharmaceuticals（NASDAQ:MIRM - Get Free Report）最近发布了其季度收益报告，日期为 8 月 7 日星期三。公司报告季度每股亏损 ($0.52)，低于分析师预期的 ($0.47)。Mirum Pharmaceuticals 的净资产收益率为-43.47%，净利润率为-40.34%。该季度公司收入为$77.90 百万，超过分析师预期的$75.03 百万。与去年同期相比，Mirum Pharmaceuticals 的季度收入增长了 107.7%。研究分析师预测，Mirum Pharmaceuticals, Inc.本财年的每股收益将达到-1.75 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些券商最近发布了关于 MIRM 的报告。JMP Securities 将 Mirum Pharmaceuticals 的目标股价从$66.00 上调至$68.00，并在 6 月 18 日星期二的研究报告中给予该股 “市场表现优异” 评级。Evercore ISI 将 Mirum Pharmaceuticals 的目标股价从$62.00 上调至$66.00，并在 8 月 8 日星期四的研究报告中给予该股 “表现优异” 评级。摩根大通将 Mirum Pharmaceuticals 的目标股价从$31.00 上调至$39.00，并在 6 月 18 日星期二的研究报告中给予该股 “超配” 评级。花旗将 Mirum Pharmaceuticals 的目标股价从$38.00 上调至$64.00，并在 6 月 18 日星期二的研究报告中给予该股 “买入” 评级。最后，摩根士丹利将 Mirum Pharmaceuticals 的目标股价从$53.00 上调至$57.00，并在 6 月 18 日星期二的研究报告中给予该股 “超配” 评级。十位研究分析师对该股给予买入评级，两位分析师给予强烈买入评级。根据 MarketBeat，Mirum Pharmaceuticals 的平均评级为 “买入”，目标股价一致预期为$56.27。</p>
<p><strong>查看我们关于 Mirum Pharmaceuticals 的最新股票报告</strong></p>
<h2>关于 Mirum Pharmaceuticals（免费报告）</h2>
<p>Mirum Pharmaceuticals, Inc.是一家生物制药公司，专注于开发和商业化用于治疗罕见和孤儿疾病的新型疗法。其主要产品候选药物是 LIVMARLI（maralixibat），一种口服和吸收极少的回肠胆酸转运蛋白（IBAT）抑制剂，已获批用于治疗美国和国际 Alagille 综合征患者的胆汁瘙痒症。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票胜过 Mirum Pharmaceuticals</li>
<li>什么是股息冠军？如何投资冠军</li>
<li>3 只杠杆 ETF，倍增回报</li>
<li>内幕交易 - 你需要了解的</li>
<li>两位巨头的故事：揭示百度和京东的价值</li>
<li>投资者如何识别并成功交易跳空股</li>
<li>AI 能力 iPhone 16 是销售超级周期的开始吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlSTQ"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和准确的报道。在发布之前，该故事已经经过 MarketBeat 的编辑团队审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 你绝对不会相信这位前华尔街内部人士在选举中发现了什么（来自 Banyan Hill Publishing）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTc1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTc1"/></p>
<h2>现在是否值得投资$1,000 在 Mirum Pharmaceuticals？</h2>
<p>在考虑 Mirum Pharmaceuticals 之前，您应该听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票，然后再更广泛市场注意到之前...而 Mirum Pharmaceuticals 并不在名单上。</p>
<p>虽然 Mirum Pharmaceuticals 目前在分析师中有一个 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

MIRM

<p>First Turn Management LLC 在第二季度将其在 Mirum Pharmaceuticals, Inc.（NASDAQ：MIRM）的持股比例减少了 26.6％，现持有 703,398 股。该公司持有的 Mirum 股份占其投资组合的 3.9％。其他投资者，包括 Quest Partners LLC 和亚利桑那州退休系统，也调整了他们的持股比例。Mirum 的股价开盘为 22.13 美元，52 周股价范围为 14.14 美元至 23.23 美元。该公司报告了年同比增长 107.7％的营收，但未达到每股收益预期。分析师普遍对该股票给予了积极评价，最近有几家机构提高了价格目标</p>

<p>First Turn Management LLC decreased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 26.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 703,398 shares of the company's stock after selling 255,256 shares during the period. Mirum Pharmaceuticals comprises 3.9% of First Turn Management LLC's portfolio, making the stock its 5th largest holding. First Turn Management LLC owned about 1.49% of Mirum Pharmaceuticals worth $24,049,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>First Turn Management LLC 在第二季度减持 Mirum Pharmaceuticals, Inc.（NASDAQ:MIRM - Free Report）股份，根据该公司最新提交给证券交易委员会的第 13F 表格，持股比例下降了 26.6%。该公司在此期间卖出了 255,256 股，持有 703,398 股公司股票。Mirum Pharmaceuticals 占 First Turn Management LLC 投资组合的 3.9%，是其第 5 大持仓。根据最新提交给证券交易委员会的文件，First Turn Management LLC 持有的 Mirum Pharmaceuticals 价值约为$24,049,000。</p>
</div><p>Get <strong>Mirum Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Mirum Pharmaceuticals</strong> 警报：</p>
</div><p>A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MIRM. Quest Partners LLC increased its holdings in Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company's stock valued at $39,000 after buying an additional 1,127 shares during the last quarter. StepStone Group LP purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at approximately $135,000. NEOS Investment Management LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at approximately $220,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 66.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 8,952 shares of the company's stock worth $225,000 after purchasing an additional 3,558 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in shares of Mirum Pharmaceuticals by 10.6% in the second quarter. Arizona State Retirement System now owns 9,210 shares of the company's stock worth $315,000 after purchasing an additional 883 shares in the last quarter.</p>
<div class="lb-trans"><p>一些其他对冲基金和其他机构投资者最近也增加或减少了他们对 MIRM 的持股。Quest Partners LLC 在第二季度将其对 Mirum Pharmaceuticals 的持股增加了 7,513.3%。Quest Partners LLC 现在拥有 1,142 股公司股票，价值$39,000，上季度购入了 1,127 股。StepStone Group LP 在第四季度购入了 Mirum Pharmaceuticals 的新股份，价值约为$135,000。NEOS Investment Management LLC 在第四季度购入了 Mirum Pharmaceuticals 的新股份，价值约为$220,000。中国通用资产管理有限公司在第一季度将其对 Mirum Pharmaceuticals 的持股增加了 66.0%。中国通用资产管理有限公司现在拥有 8,952 股公司股票，价值$225,000，上季度购入了 3,558 股。最后，亚利桑那州退休系统在第二季度将其对 Mirum Pharmaceuticals 的持股增加了 10.6%。亚利桑那州退休系统现在拥有 9,210 股公司股票，价值$315,000，上季度购入了 883 股。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士的买卖行为</h2>
</div><p>In other Mirum Pharmaceuticals news, insider Pamela Vig sold 30,559 shares of the business's stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $34.00, for a total value of $1,039,006.00. Following the completion of the sale, the insider now directly owns 27,406 shares of the company's stock, valued at approximately $931,804. The transaction was disclosed in a filing with the SEC, which is available through this link. 22.87% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Mirum Pharmaceuticals 的消息中，内部人士 Pamela Vig 在 6 月 24 日星期一进行了一笔交易，卖出了 30,559 股公司股票。这些股票的平均价格为$34.00，总价值为$1,039,006.00。交易完成后，该内部人士直接持有公司股票 27,406 股，价值约为$931,804。该交易已在提交给 SEC 的文件中披露，可以通过此链接查看。公司股份的 22.87% 归公司内部人士所有。</p>
</div><h2>Mirum Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Mirum Pharmaceuticals 股票表现</h2>
</div><p>MIRM stock opened at $41.13 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $45.23. The company has a current ratio of 3.28, a quick ratio of 3.09 and a debt-to-equity ratio of 1.34. The company has a fifty day simple moving average of $40.46 and a two-hundred day simple moving average of $31.57.</p>
<div class="lb-trans"><p>MIRM 股票周五开盘价为$41.13。Mirum Pharmaceuticals, Inc.的 52 周最低价为$23.14，52 周最高价为$45.23。公司的流动比率为 3.28，速动比率为 3.09，负债权益比为 1.34。公司的五十天简单移动平均为$40.46，两百天简单移动平均为$31.57。</p>
</div><p>Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.05). Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The firm had revenue of $77.90 million for the quarter, compared to analysts' expectations of $75.03 million. During the same period in the prior year, the firm posted ($0.92) earnings per share. Mirum Pharmaceuticals's revenue for the quarter was up 107.7% on a year-over-year basis. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.75 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals（NASDAQ:MIRM - Get Free Report）最近发布了其季度收益报告，日期为 8 月 7 日星期三。公司报告季度每股亏损 ($0.52)，低于分析师预期的 ($0.47)。Mirum Pharmaceuticals 的净资产收益率为-43.47%，净利润率为-40.34%。该季度公司收入为$77.90 百万，超过分析师预期的$75.03 百万。与去年同期相比，Mirum Pharmaceuticals 的季度收入增长了 107.7%。研究分析师预测，Mirum Pharmaceuticals, Inc.本财年的每股收益将达到-1.75 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages have recently issued reports on MIRM. JMP Securities increased their price objective on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Tuesday, June 18th. Evercore ISI increased their price objective on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, August 8th. JPMorgan Chase &amp; Co. increased their price objective on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, June 18th. Citigroup increased their price objective on shares of Mirum Pharmaceuticals from $38.00 to $64.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, June 18th. Finally, Morgan Stanley increased their price objective on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, June 18th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Mirum Pharmaceuticals has an average rating of &#34;Buy&#34; and a consensus target price of $56.27.</p>
<div class="lb-trans"><p>一些券商最近发布了关于 MIRM 的报告。JMP Securities 将 Mirum Pharmaceuticals 的目标股价从$66.00 上调至$68.00，并在 6 月 18 日星期二的研究报告中给予该股 “市场表现优异” 评级。Evercore ISI 将 Mirum Pharmaceuticals 的目标股价从$62.00 上调至$66.00，并在 8 月 8 日星期四的研究报告中给予该股 “表现优异” 评级。摩根大通将 Mirum Pharmaceuticals 的目标股价从$31.00 上调至$39.00，并在 6 月 18 日星期二的研究报告中给予该股 “超配” 评级。花旗将 Mirum Pharmaceuticals 的目标股价从$38.00 上调至$64.00，并在 6 月 18 日星期二的研究报告中给予该股 “买入” 评级。最后，摩根士丹利将 Mirum Pharmaceuticals 的目标股价从$53.00 上调至$57.00，并在 6 月 18 日星期二的研究报告中给予该股 “超配” 评级。十位研究分析师对该股给予买入评级，两位分析师给予强烈买入评级。根据 MarketBeat，Mirum Pharmaceuticals 的平均评级为 “买入”，目标股价一致预期为$56.27。</p>
</div><p><strong>Check Out Our Latest Stock Report on Mirum Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Mirum Pharmaceuticals 的最新股票报告</strong></p>
</div><h2>About Mirum Pharmaceuticals (Free Report)</h2>
<div class="lb-trans"><h2>关于 Mirum Pharmaceuticals（免费报告）</h2>
</div><p>Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals, Inc.是一家生物制药公司，专注于开发和商业化用于治疗罕见和孤儿疾病的新型疗法。其主要产品候选药物是 LIVMARLI（maralixibat），一种口服和吸收极少的回肠胆酸转运蛋白（IBAT）抑制剂，已获批用于治疗美国和国际 Alagille 综合征患者的胆汁瘙痒症。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Mirum Pharmaceuticals</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>3 Leveraged ETFs to Multiply Returns</li>
<li>Insider Trading - What You Need to Know</li>
<li>A Tale of Two Titans: Unveiling the Value in Baidu and JD.com</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票胜过 Mirum Pharmaceuticals</li>
<li>什么是股息冠军？如何投资冠军</li>
<li>3 只杠杆 ETF，倍增回报</li>
<li>内幕交易 - 你需要了解的</li>
<li>两位巨头的故事：揭示百度和京东的价值</li>
<li>投资者如何识别并成功交易跳空股</li>
<li>AI 能力 iPhone 16 是销售超级周期的开始吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlSTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MIRM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和准确的报道。在发布之前，该故事已经经过 MarketBeat 的编辑团队审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ You won’t believe what this ex-Wall Street insider discovered about the election (From Banyan Hill Publishing)(Ad)</p>
<div class="lb-trans"><p>→ 你绝对不会相信这位前华尔街内部人士在选举中发现了什么（来自 Banyan Hill Publishing）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTc1" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9575&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Mirum Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Mirum Pharmaceuticals？</h2>
</div><p>Before you consider Mirum Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Mirum Pharmaceuticals 之前，您应该听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票，然后再更广泛市场注意到之前...而 Mirum Pharmaceuticals 并不在名单上。</p>
</div><p>While Mirum Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Mirum Pharmaceuticals 目前在分析师中有一个 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

First Turn Management LLC 降低了其在 Mirum Pharmaceuticals, Inc.（纳斯达克股票代码：MIRM）的持仓